The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine, are the cornerstone of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with numerous side ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Some cancer patients react very badly to commonly used chemotherapies — but there is a test that can identify those patients. So why isn't this test being used? This is the question currently being ...

The European Medicines Agency (EMA) has started a review into the screening of patients before they begin treatment with certain drugs. Most of the drugs in question are chemotherapies, and they ...

Impact of targeted education on adverse drug reaction documentation in cancer center sites. This is an ASCO Meeting Abstract from the 2023 ASCO Quality Care Symposium. This abstract does not include a ...

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...